Praxis Precision Medicines, Inc.
PRAX NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 6, 2026
ET
EPS Est.
-3.67
EPS Actual
-2.87
Revenue Est.
$1.3M
Revenue Actual
--
Next Earnings Report
Date
Nov 4, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
-3.53
Revenue Est.
$130769
Company Overview
Praxis Precision Medicines, Inc. (ticker PRAX) is listed on NASDAQ with a market cap of about $10.48B. Its next earnings report (FY2026 Q3) is expected on Nov 4, 2026 (ET), Pre-market, with consensus EPS of -3.53. In the last 15 reported quarters, EPS beat consensus estimates 9 times.
Actual EPS TrendRecently15Term · Feb 7, 2023 → Aug 6, 2026
Feb 7, 2023Range: -13.04 ~ -1.74Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | -3.67 | Above forecast↑-2.87 | $1.3M | -- |
| May 7, 2026 | -- | -3.58 | -3.20 | $100000 | -- |
| Feb 19, 2026 | -- | -3.13 | -3.50 | $66667 | -- |
| Nov 5, 2025 | -- | -3.45 | -3.36 | $256090 | -- |
| Aug 4, 2025 | -- | -3.40 | -3.31 | $59440 | -- |
| May 2, 2025 | -- | -3.20 | -3.29 | $198800 | -- |
| Feb 28, 2025 | -- | -2.76 | -2.94 | $297880 | $7.5M |
| Nov 6, 2024 | -- | -2.01 | Below forecast↓-2.75 | $365000 | $302000 |
| Aug 13, 2024 | -- | -2.38 | Above forecast↑-1.74 | $830000 | $357000 |
| May 13, 2024 | -- | -2.01 | Below forecast↓-2.84 | $1.6M | $431000 |
| Mar 5, 2024 | -- | -3.15 | -2.97 | $50000 | $515000 |
| Nov 7, 2023 | -- | -5.25 | Above forecast↑-2.70 | -- | $468000 |
| Aug 9, 2023 | -- | -9.90 | Above forecast↑-7.35 | -- | $781000 |
| May 11, 2023 | -- | -11.24 | -10.64 | -- | $683000 |
| Feb 7, 2023 | -- | -10.94 | Below forecast↓-13.04 | -- | -- |
Original Filings (SEC)
10-Q2026-08-06 ↗
8-K2026-08-06 ↗
8-K2026-07-07 ↗
8-K2026-07-02 ↗
8-K2026-06-29 ↗
8-K2026-06-22 ↗
8-K2026-06-12 ↗
8-K2026-06-01 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
